| Name | Title | Contact Details |
|---|
As part of the state`s premier academic medical center, University of Missouri Health Care offers a full spectrum of care, ranging from primary care to highly specialized, multidisciplinary treatment for patients with the most severe illnesses and injuries. Patients from each of Missouri`s 114 counties are served by approximately 6,000 physicians, nurses and health care professionals at MU Health Care. MU Health Care is a part of University of Missouri Health System, which also includes the MU School of Health Professions, the MU School of Medicine, the MU Sinclair School of Nursing and University Physicians practice plan. University Hospital includes: The Frank L. Mitchell Jr., MD Trauma Center. A nationally accredited Cycle II Chest Pain Center and a nationally accredited Primary Stroke Center, the George D. Peak Memorial Burn and Wound Center. University of Missouri Women`s and Children`s Hospital is Missouri`s only hospital dedicated to women and children. It is the largest pediatric health care facility in mid-Missouri. Ellis Fischel Cancer Center is Missouri`s only hospital dedicated solely to cancer care. Missouri Orthopaedic Institute is the newest and largest freestanding orthopaedic center in mid-Missouri. The Missouri Psychiatric Center offers short-term, intensive inpatient treatment services for adults, adolescents and children at our facility adjacent to University Hospital.
Our name, Monogram, symbolizes the personalized focus of our services. While the application of the latest technology and data science is critical to our success, we never lose sight that healthcare is ultimately about trusted individual relationships between healthcare professionals and their patients. Unfortunately, individuals living with advanced CKD and ESRD are negatively impacted by well entrenched systematic forces such as perverse economic incentives, poor adherence to evidence-based care, and a lack of sensitivity to the negative impacts of social determinants of health. The 21st Century Cures Act is a seminal piece of legislation designed to shift individuals living with ESRD from FFS Medicare into managed care and reverse decades and decades of sub-optimal outcomes. Monogram was born with a vision to serve health plans and other sponsors of health care and solve for these systemic problems. Our mission is to improve clinical outcomes by predicting the onset of CKD and ESRD, slowing its progression, and reducing hospitalizations, morbidity and mortality. We are founded and operated by a core group of former government programs health plan executives, including our CEO, Michael Uchrin, a world-renown nephrologist and author of over 200 published pieces of research, Dr. Raymond Hakim, and former US Senator Bill Frist M.D., a retired cardiac surgeon and recognized leader for improving the quality of care provided to human beings across the world. We welcome all stakeholders in the CKD | ESRD ecosystem to join us in our mission to measurably improve outcomes for individuals living with these conditions.
Sinaiko Healthcare Consulting is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Block Imaging International is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Lansing, MI. To find more information about Block Imaging International, please visit www.blockimaging.com
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.